Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations

NCT03486496 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT03486496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03486496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 5, 2018
Completion date
February 1, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutation, lung adenocarcinoma